Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318119 | 1.00 | GHSR (0.53) | GHSRCTSCADAM17CTSBCTSS | |
| SCHEMBL6317099 | 0.91 | GHSR (0.48) | GHSRS1PR1 | |
| SCHEMBL7174422 | 0.91 | GHSR (0.48) | GHSRS1PR1 | |
| SCHEMBL6317105 | 0.91 | GHSR (0.48) | GHSRS1PR1 | |
| SCHEMBL6317915 | 0.86 | GHSR (0.46) | GHSR | |
| SCHEMBL6317908 | 0.86 | GHSR (0.46) | GHSR | |
| SCHEMBL6318768 | 0.85 | GHSR (0.72) | GHSRCTSC | |
| SCHEMBL6318779 | 0.85 | GHSR (0.72) | GHSRCTSC | |
| SCHEMBL6324203 | 0.84 | GHSR (0.35) | GHSRCTSCADAM17CTSSCTSK | |
| SCHEMBL6318260 | 0.82 | GHSR (0.73) | GHSRCTSCCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | claimed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | claimed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | claimed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | claimed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | claimed |
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | disclosed |
| US-6555570-B2 | Growth hormone secretagogous with improved bioavailability | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | APOB, LDLR, LPL | GHSR 586/4885CTSC 1478/4885ADAM17 4774/4885 |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | GHSR 2/4885CTSC 242/4885ADAM17 1822/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | GHSR 2/4885CTSC 234/4885ADAM17 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.